Stryker Projects 6.5% to 7% Organic Sales Growth for 2026 Amid U.S. Expansion of Versius
Stryker (SYK) reported third-quarter organic sales growth of 7.7%, driven largely by a 9.1% increase in the MedSurg and Neurotechnology segment and a 5.9% rise in Orthopaedics. Despite these gains, management noted that overall results fell short of certain expectations. Looking ahead to 2026, the company anticipates organic net sales growth between 6.5% and 7%. A key component of this long-term strategy involves scaling the Versius robotic system within the United States market to drive future revenue.
Tickers: $SYK
Topics: MedSurg and Neurotechnology organic sales growth Orthopaedics quarterly earnings